Currently Viewing:
Supplements New Approaches to the Management and Treatment of Insomnia
Managing Insomnia in an Evolving Marketplace
Lawrence D. Goldberg, MD, MBA
The Economic Impact of Insomnia in Managed Care: A Clearer Picture Emerges
D. S. Pete Fullerton, PhD, RPh
Strategies for Treating Chronic Insomnia
Anna K. Morin, PharmD
The Epidemiology and Diagnosis of Insomnia
Karl Doghramji, MD
The Impact and Prevalence of Chronic Insomnia and Other Sleep Disturbances Associated With Chronic Illness
Sonia Ancoli-Israel, PhD
Currently Reading
Participating Faculty

Participating Faculty

This supplement to The American Journal of Managed Care discusses current treatment strategies for managing insomnia and their impact on economic outcomes.

Faculty
Sonia Ancoli-Israel, PhD
Professor of Psychiatry
University of California San Diego
School of Medicine
Director
Sleep Disorder Clinic
Veterans Affairs San Diego Healthcare System
San Diego, California

Karl Doghramji, MD
Professor of Psychiatry
Jefferson Medical College
Director
Sleep Disorders Center
Thomas Jefferson University
Philadelphia, Pennsylvania

D. S. Pete Fullerton, PhD, RPh
Consultant
Strategic Pharmacy Innovations
 The University of Washington
Seattle, Washington

Lawrence D. Goldberg, MD, MBA
President
Goldberg, MD + Associates
Battle Ground, Washington

Anna K. Morin, PharmD
Assistant Professor
Department of Pharmacy Practice
Massachusetts College of Pharmacy and Health Sciences
Worcester, Massachusetts

Faculty Disclosure

It is the policy of The American Journal of Managed Care to have all faculty who participate in programs sponsored by pharmaceutical companies disclose any real or apparent conflicts of interest. These participants have declared the following affiliations with corporate organizations:

  • Sonia Ancoli-Israel, PhD
      Consultant/Honorarium/Speaker's bureau:
    • Cephalon, Inc
    • King Pharmaceuticals, Inc
    • Pfizer Inc
    • Sanofi-Aventis
    • Sepracor, Inc
    • Takeda Pharmaceuticals
    • North America, Inc
      Consultant/Honorarium:
    • Acadia
    • Merck & Co, Inc
    • Neurogen, Inc
    • Somaxon
  • Karl Doghramji, MD
      Advisory board/Speaker's bureau:
    • GlaxoSmithKline
      Consultant:
    • Pfizer Inc
    • Neurocrine Bioscience
      Consultant/Speaker's bureau:
    • Sanofi
    • Sepracor, Inc
    • Takeda Pharmaceuticals
    • North America, Inc
      Speaker's bureau/Stock/Other financial options:
    • Forest Laboratories
      Stock/Other financial options:
    • Cephalon, Inc
    • Medco Health
    • Merck & Co, Inc

The following participants report no relevant financial relationships with pharmaceutical companies:

  • D. S. Pete Fullerton, PhD, RPh
  • Lawrence D. Goldberg, MD, MBA
  • Anna K. Morin, PharmD

Signed disclosures are on file at the offices of The American Journal of Managed Care, Jamesburg, New Jersey.

This publication was made possible by funding from Sepracor, Inc.

•••

The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

PDF
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up